Avana (Avanafil) Tablets: Strength, Composition and Product Informationn

Avana (avanafil) tablets are an oral pharmaceutical formulation containing avanafil as the active pharmaceutical ingredient (API). Avanafil belongs to a class of medicines known as phosphodiesterase type 5 (PDE5) inhibitors. Product specifications, approved indications and supply conditions should always be verified against the relevant product registration and approved prescribing information for the intended market.

For pharmaceutical procurement teams, importers, distributors and qualified healthcare professionals in Singapore, reviewing the product’s strength, composition, quality documentation and regulatory status is an essential part of responsible medicine sourcing.

Avanafil Tablet Strengths

Avanafil tablets are available in several strengths in certain markets. Commonly documented strengths include:

Avanafil 50 mg tablets

Avanafil 100 mg tablets

Avanafil 200 mg tablets

Availability depends on the specific product and its regulatory authorisation. These strengths should not be interpreted as confirmation that every formulation is registered or available for supply in Singapore.

Composition of Avana Tablets

Active ingredient: Avanafil.

Inactive ingredients: Excipients vary by manufacturer and formulation. Examples documented in certain avanafil tablet formulations include mannitol, fumaric acid, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate and sodium bicarbonate.

The exact composition of the Avana product must be confirmed using its own approved product insert, packaging information and batch-specific documentation. Do not assume that ingredients listed for another avanafil formulation are identical.

Product Quality and Singapore Regulatory Considerations

Before considering pharmaceutical supply in Singapore, verify the product’s registration status, authorised indications, manufacturing details, applicable import and wholesale licences, and required quality documentation.

Depending on the transaction, relevant documents may include a Certificate of Analysis (CoA), batch details, manufacturing information, stability data and other supporting technical records. Documentation requirements should be confirmed with the relevant regulatory and procurement teams.

Product information published online should remain accurate, traceable and consistent with the applicable approved documentation. Registration in another country does not automatically authorise import, sale or supply in Singapore.

Frequently Asked Questions

1. What is the active ingredient in Avana tablets?

The stated active ingredient is avanafil. Confirm the identity and quantity against the packaging and approved product documentation.

2. What strengths of avanafil tablets are available?

Commonly documented strengths are 50 mg, 100 mg and 200 mg. Actual availability and authorised presentations depend on the product and market.

3. Are all avanafil tablets made with the same excipients?

No. Inactive ingredients can differ between formulations and manufacturers. Refer to the specific product insert for the complete composition.

4. Can avanafil tablets be imported into Singapore?

Importation and supply depend on Singapore’s applicable therapeutic-product registration and dealer-licensing requirements. Check the product’s regulatory status and obtain the necessary authorisations before proceeding.

5. What documents should a pharmaceutical buyer review?

Depending on the transaction, buyers may need product specifications, a Certificate of Analysis, batch information, manufacturing documentation and evidence of applicable regulatory authorisation.

6. Can this product page be used as a public sales advertisement?

Not without regulatory assessment. Singapore restricts public advertising of prescription-only medicines, including advertising related to sexual-function conditions. A professional or trade-only reference must also meet applicable requirements.

Disclaimer: This page provides general product and trade-reference information. It does not replace approved prescribing information, professional medical advice or Singapore regulatory guidance.